EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐World Experience of Efficacy and Tolerability of Continuous Infusion Ifosfamide for Advanced Soft Tissue and Bone Sarcoma Patients: A Single Centre Retrospective Cohort

Ilaria Mascagni iD, Alice Laffi, Maria Susanna Grimaudo, Ferdinando Carlo Maria Cananzi iD, Laura Samà, Salvatore Lorenzo Renne iD, Federico D'Orazio, Pierina Navarria, Elena Clerici, Carlo Carnaghi, Sara Farinatti iD, Erika Stucchi und 5 weitere

Cancer Medicine · 2026

DOI: 10.1002/cam4.71614 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Ilaria Mascagni und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. Hauptthemen laut MEDLINE: Ifosfamide, Bone Neoplasms, Sarcoma, Antineoplastic Agents, Alkylating. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the absence of randomized trials, selecting second or later‐line therapies in advanced sarcoma generally hinges on histology, patient performance status, and toxicity profile. We herein report a real‐world sarcoma referral center experience on continuous infusion Ifosfamide (ciIFO), in advanced Soft tissue sarcomas (STS) and bone sarcomas (BS) patients, assessing both efficacy and toxicity profile.

Methods

We retrospectively collected data of STS and BS patients treated with ciIFO (14 g/m 2 as a 14‐day continuous infusion every 4 weeks) at our Institute from January 2013 to April 2023. The analysis included patients’ demographic and clinical characteristics, pathology details, treatment history, radiological response rates (RR), and toxicities per Common Terminology Criteria for Adverse Events (CTCAE) v5.

Results

Ninety eight patients were included in the analysis. Median age at diagnosis was 49 years, 61% had previously received ifosfamide (IFO) and 83% anthracycline in earlier lines of treatment. Disease control rate (DCR) was 32%, with 9 PR and 22 stable disease (SD). Synovial sarcomas had the best (DCR) (60%). No statistically significant differences in DCR were seen according to sex, previous exposure to ifosfamide‐based CT, or ciIFO treatment line. mPFS was 3.0 months; mOS was 11.2 months. ciIFO was well tolerated, with an 11% discontinuation rate and no severe renal toxicity observed. Conclusions ciIFO showed activity across different lines of therapy, achieving a DCR of 32%, and appeared better tolerated than standard‐dose IFO regimens, even in a cohort of heavily pretreated patients (18% had an Eastern Cooperative Oncology Group performance status (ECOG PS) ≥ 2). Synovial and bone sarcoma patients derived the greatest benefit (6‐month PFS of 45% in both groups).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IfosfamideBone NeoplasmsSarcomaAntineoplastic Agents, AlkylatingSoft Tissue NeoplasmsOsteosarcomaHumansFemaleRetrospective StudiesMiddle AgedMaleAdultAgedInfusions, IntravenousYoung AdultTreatment Outcome

Stichwörter der Autor:innen

advanced sarcomabone sarcomacontinuous infusion ifosfamidereal‐world datasoft tissue sarcoma

Substanzen

IfosfamideAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
  • Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Division of Medical Oncology, Humanitas Gavazzeni, Bergamo, Italy.
  • Sarcoma, Melanoma and Rare Tumor Surgery Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Department of Pathology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Diagnostic Radiology Department, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

ORCID-Profile: Ilaria Mascagni, Ferdinando Carlo Maria Cananzi, Salvatore Lorenzo Renne, Sara Farinatti

Förderung

  • NCI NIH HHS

Zitieren

APA

Mascagni, I., Laffi, A., Grimaudo, M. S., Cananzi, F. C. M., Samà, L., Renne, S. L., D'Orazio, F., Navarria, P., Clerici, E., Carnaghi, C., Farinatti, S., Stucchi, E., Le Moli, M., Giordano, L., Maki, R. G., Santoro, A., & Bertuzzi, A. F. (2026). Real‐World Experience of Efficacy and Tolerability of Continuous Infusion Ifosfamide for Advanced Soft Tissue and Bone Sarcoma Patients: A Single Centre Retrospective Cohort. Cancer Medicine. https://doi.org/10.1002/cam4.71614

Vancouver

Mascagni I, Laffi A, Grimaudo MS, Cananzi FCM, Samà L, Renne SL, et al. Real‐World Experience of Efficacy and Tolerability of Continuous Infusion Ifosfamide for Advanced Soft Tissue and Bone Sarcoma Patients: A Single Centre Retrospective Cohort. Cancer Medicine. 2026. doi:10.1002/cam4.71614

BibTeX
@article{Mascagni2026,
  author = {Mascagni, Ilaria and Laffi, Alice and Grimaudo, Maria Susanna and Cananzi, Ferdinando Carlo Maria and Samà, Laura and Renne, Salvatore Lorenzo and D'Orazio, Federico and Navarria, Pierina and Clerici, Elena and Carnaghi, Carlo and Farinatti, Sara and Stucchi, Erika and Le Moli, Marialudovica and Giordano, Laura and Maki, Robert G and Santoro, Armando and Bertuzzi, Alexia Francesca},
  title = {Real‐World Experience of Efficacy and Tolerability of Continuous Infusion Ifosfamide for Advanced Soft Tissue and Bone Sarcoma Patients: A Single Centre Retrospective Cohort},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.71614}
}
Kostenlos starten →